Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Neuroendocrine tumors | D018358 | EFO_1001901 | D3A.8 | 17 | 25 | 7 | 1 | 11 | 54 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Carcinoid tumor | D002276 | — | D3A.00 | — | 3 | 2 | — | — | 5 |
Gastro-enteropancreatic neuroendocrine tumor | C535650 | — | — | 1 | 1 | 2 | — | — | 3 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Neuroendocrine carcinoma | D018278 | — | — | 1 | 6 | — | — | — | 6 |
Pancreatic neoplasms | D010190 | EFO_0003860 | C25 | 3 | 4 | — | — | 1 | 6 |
Paraganglioma | D010235 | — | — | 1 | 4 | — | — | — | 4 |
Meningioma | D008579 | EFO_0003098 | D32.9 | 1 | 4 | — | — | — | 4 |
Pheochromocytoma | D010673 | — | — | 1 | 3 | — | — | — | 3 |
Neoplasms | D009369 | — | C80 | — | 2 | — | — | 1 | 3 |
Merkel cell carcinoma | D015266 | EFO_1001471 | C4A | 1 | 2 | — | — | — | 2 |
Neuroblastoma | D009447 | EFO_0000621 | — | 1 | 1 | — | — | — | 2 |
Breast neoplasms | D001943 | EFO_0003869 | C50 | — | 1 | — | — | — | 1 |
Pituitary neoplasms | D010911 | — | — | — | 1 | — | — | — | 1 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Thymoma | D013945 | — | — | 1 | — | — | — | — | 1 |
Mesothelioma | D008654 | — | C45 | 1 | — | — | — | — | 1 |
Glioblastoma | D005909 | EFO_0000515 | — | 1 | — | — | — | — | 1 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Thyroid neoplasms | D013964 | EFO_0003841 | — | — | — | — | — | 1 | 1 |
Hyperthyroidism | D006980 | — | E05.9 | — | — | — | — | 1 | 1 |
Stomach neoplasms | D013274 | EFO_0003897 | C16 | — | — | — | — | 1 | 1 |
Gastrointestinal neoplasms | D005770 | — | C26.9 | — | — | — | — | 1 | 1 |
Digestive system neoplasms | D004067 | — | — | — | — | — | — | 1 | 1 |
Gastrointestinal diseases | D005767 | — | — | — | — | — | — | 1 | 1 |
Germ cell and embryonal neoplasms | D009373 | — | — | — | — | — | — | 1 | 1 |
Endocrine system diseases | D004700 | EFO_0001379 | E34.9 | — | — | — | — | 1 | 1 |
Neoplasms by histologic type | D009370 | — | — | — | — | — | — | 1 | 1 |
Intestinal neoplasms | D007414 | — | C26.0 | — | — | — | — | 1 | 1 |
Drug common name | Lutetium dotatate lu-177 |
INN | — |
Description | Lutetium (177Lu) oxodotreotide (INN) or 177Lu DOTA-TATE, trade name Lutathera, is a chelated complex of a radioisotope of the element lutetium with DOTA-TATE, used in peptide receptor radionuclide therapy (PRRT). Specifically, it is used in the treatment of cancers which express somatostatin receptors.
|
Classification | Small molecule |
Drug class | Antineoplastic agent |
Image (chem structure or protein) | |
Structure (InChI/SMILES or Protein Sequence) | — |
PDB | — |
CAS-ID | — |
RxCUI | — |
ChEMBL ID | CHEMBL3989924 |
ChEBI ID | — |
PubChem CID | — |
DrugBank | DB13985 |
UNII ID | — |